Medtronic Inc. (MDT) recently launched a new TSRH 3Dx Spinal System, which is a hook, rod and screw system used in complex spinal procedures. The system offers two screws designed to address multiple pathologies. The Multi Planar Adjusting (MPA) Screw gives surgeons the flexibility of a variable angle posted screw for targeted, controlled correction maneuvers. The OSTEOGRIP Screw enhances bone fixation by incorporating a dual-lead thread pattern that reduces toggle at the bone-screw interface.

The new pedicle screw system has a unique technology that addresses multiple spinal pathologies, from degenerative disc disease to spinal deformity. The product offers an alternative to patients for spinal stabilization with fusion. It works for patients suffering from degenerative spinal conditions, deformity, or injury of the thoracic, lumbar, and sacral spine. The TSRH Spinal System also provides Chromaloy rods and a minimally invasive capability.

We think that the new product will be widely accepted by

...

TranS1 Inc. (TSON) has announced that it expects revenues to be approximately $6.8 million to $6.9 million in the third quarter of 2009 compared to $6 million reported in the year-ago quarter. Results for the quarter are expected to be released on Oct 29, 2009.  While revenues are expected to increase from the year-ago period, they are still predicted to be lower than the previous guidance of $7.4 million to $7.9 million. The lower guidance is primarily based on weak sales of the company’s AxiaLIF lumbar fusion device due to insurance reimbursement concerns.  However, management considers these low revenues as a short-term event and is confident about long-term growth primarily due to the expanding minimally invasive spine surgery market.  TranS1 is working on educating existing and potential customers about the utilities of the AxiaLIF lumbar fusion device to increase its sales. The device allows surgeons ...

TranS1 Inc. (TSON) announced that it expects revenue to be roughly in the range of $7.9 million to $8.0 million in the second quarter of this year, lower than its previous guidance of $8.7 million to $9.0 million but approximately 33% higher than the revenue in the year-ago quarter.   TranS1 believes that its revenue is likely to be affected by the reimbursement uncertainty surrounding its AxiaLIF procedure. The company expects to release its second quarter results on July 30, 2009, after the close.   TranS1 is engaged in designing, developing and marketing minimally invasive products that utilize its proprietary TranS1 surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine.   TranS1 is badly hurt by a reimbursement uncertainty surrounding its AxiaLIF procedure. We believe expected near-term reimbursement changes would make the pre-certification and administration process time-consuming and could create some revenue ...